• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    1/10/24 9:08:13 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care
    Get the next $GKOS alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2 )*

                

    Glaukos Corp


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    377322102


    (CUSIP Number)

    December 29, 2023


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 377322102

    1. NAMES OF REPORTING PERSONS

    Wellington Management Group LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Massachusetts

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 1,096,068
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 1,340,500
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,340,500
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.75%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 377322102

    1. NAMES OF REPORTING PERSONS

    Wellington Group Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 1,096,068
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 1,340,500
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,340,500
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.75%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 377322102

    1. NAMES OF REPORTING PERSONS

    Wellington Investment Advisors Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 1,096,068
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 1,340,500
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,340,500
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.75%
    12. TYPE OF REPORTING PERSON

    HC

    Item 1.
    (a) Name of Issuer
    Glaukos Corp
    (b) Address of Issuer's Principal Executive Offices
    229 Avenida Fabricante
    San Clemente, CA 92672
    Item 2.
    (a) Name of Person Filing
    Wellington Management Group LLP
    Wellington Group Holdings LLP
    Wellington Investment Advisors Holdings LLP
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Company LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    Wellington Management Group LLP - Massachusetts
    Wellington Group Holdings LLP - Delaware
    Wellington Investment Advisors Holdings LLP - Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    377322102
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [ ] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    See the responses to Item 9 on the attached cover pages.
    (b) Percent of Class:
    See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote See the responses to Item 6 on the attached cover pages.
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of See the responses to Item 8 on the attached cover pages.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Exhibit A directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:

    Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    See attached Exhibit A.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: January 10, 2024

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: January 10, 2024

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: January 10, 2024


    Exhibit A

    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

    Wellington Group Holdings LLP – HC
    Wellington Investment Advisors LLP – HC
    Wellington Management Global Holdings, Ltd. - HC

    One or more of the following investment advisers (the “Wellington Investment Advisers”):

    Wellington Management Company LLP – IA
    Wellington Management Canada LLC – IA
    Wellington Management Singapore Pte Ltd – IA
    Wellington Management Hong Kong Ltd – IA
    Wellington Management International Ltd – IA
    Wellington Management Japan Pte Ltd – IA
    Wellington Management Australia Pty Ltd - IA

    The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.


    EXHIBIT B

    JOINT FILING AGREEMENT

    The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Glaukos Corp is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.


    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: January 10, 2024

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: January 10, 2024

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: January 10, 2024

    Get the next $GKOS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GKOS

    DatePrice TargetRatingAnalyst
    5/1/2025$86.00Overweight → Equal Weight
    Wells Fargo
    2/19/2025$140.00 → $200.00Neutral → Outperform
    Mizuho
    12/11/2024$132.00 → $162.00Neutral → Buy
    Citigroup
    12/6/2024$182.00Buy
    UBS
    12/2/2024$120.00Equal-Weight → Underweight
    Morgan Stanley
    7/10/2024$132.00Buy → Neutral
    Citigroup
    5/6/2024$84.00 → $125.00Hold → Buy
    Jefferies
    12/21/2023$66.00 → $91.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $GKOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Glaukos downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00

      5/1/25 7:44:23 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos upgraded by Mizuho with a new price target

      Mizuho upgraded Glaukos from Neutral to Outperform and set a new price target of $200.00 from $140.00 previously

      2/19/25 7:02:55 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos upgraded by Citigroup with a new price target

      Citigroup upgraded Glaukos from Neutral to Buy and set a new price target of $162.00 from $132.00 previously

      12/11/24 7:52:08 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for IDOSE TR issued to GLAUKOS CORP

      Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

      12/15/23 11:41:09 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • FDA Approval for TRAVOPROST issued to GLAUKOS CORP

      Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

      12/14/23 7:41:03 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hoffmeister David F exercised 25,000 shares at a strike of $32.00, increasing direct ownership by 361% to 31,918 units (SEC Form 4)

      4 - GLAUKOS Corp (0001192448) (Issuer)

      6/13/25 7:43:41 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Director Foley Mark J was granted 2,972 shares, increasing direct ownership by 64% to 57,221 units (SEC Form 4)

      4 - GLAUKOS Corp (0001192448) (Issuer)

      6/2/25 4:44:12 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Director Hoffmeister David F was granted 2,665 shares, increasing direct ownership by 63% to 6,918 units (SEC Form 4)

      4 - GLAUKOS Corp (0001192448) (Issuer)

      6/2/25 4:43:25 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    SEC Filings

    See more
    • Glaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - GLAUKOS Corp (0001192448) (Filer)

      6/3/25 4:23:59 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Glaukos Corporation

      SD - GLAUKOS Corp (0001192448) (Filer)

      5/30/25 4:45:35 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GLAUKOS Corp (0001192448) (Filer)

      5/14/25 7:00:17 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies

      Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks the Company's First Regulatory Clearances Under the New EU Regulatory Framework Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos' iStent® trabecular micro-bypass stenting platfor

      6/25/25 4:05:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • NYSE Content Advisory: Pre-Market update + S&P 500 trades within 1% of record

      NEW YORK, June 25, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Kristen Scholer delivers the pre-market update on June 25th Equities are little changed Wednesday morning after jumping by more than 1% on Tuesday. The DOW gained over 500 points while the S&P 500 sits just shy of a record high.Driving those gains were easing tensions in the Middle East, resulting in crude oil prices falling by approximately 5% during Tuesday's session. President Trump announced a ceasefire agreement on Monday night.Fed

      6/25/25 8:55:00 AM ET
      $GKOS
      $ICE
      $JBS
      Medical/Dental Instruments
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell

      Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET today, Wednesday, June 25, 2025. "Ringing the NYSE closing bell today is a proud and humbling moment for our company, commemorating ten years since our IPO and celebrating the tremendous progress we've made in advancing our mission to transform vision therapies for the benefit of patients suffering from chronic eye disease

      6/25/25 7:00:00 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Financials

    Live finance-specific insights

    See more
    • Glaukos Announces First Quarter 2025 Financial Results

      Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net sales of $88.1 million in Q1 2025 increased 31% year-over-year. U.S. Glaucoma record net sales of $59.1 million in Q1 2025 increased 41% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately

      4/30/25 4:05:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

      Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2025 financial results after the market close on Wednesday, April 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 30, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (Int

      4/9/25 7:00:00 AM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

      Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include: Record net sales of $105.5 million in Q4 2024 increased 28% year-over-year. Glaucoma record net sales of $84.1 million in Q4 2024 increased 39% year-over-year. Gross margin of approximately 73% and non-GAAP gross margin of approximately 82% in Q4 2024. Net sales of $383.5 million in FY 2024 increased 22% year-over-year. Introduced 2025 net sales guidance of $475 million to $4

      2/20/25 4:05:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Leadership Updates

    Live Leadership Updates

    See more
    • OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

      NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

      1/4/23 8:00:00 AM ET
      $BLU
      $GKOS
      $INSP
      $NTLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

      Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th

      12/20/21 4:15:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

      SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis

      3/1/21 4:10:00 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care

    $GKOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

      SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

      11/14/24 1:21:45 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

      SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

      2/14/24 3:55:55 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

      SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

      2/13/24 5:41:34 PM ET
      $GKOS
      Medical/Dental Instruments
      Health Care